Korean J Pancreas Biliary Tract.  2018 Jul;23(3):108-115. 10.15279/kpba.2018.23.3.108.

Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study

  • 1Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. leonkim80@naver.com


This study aimed to compare the outcomes of patients who received systemic chemotherapy or chemoradiotherapy as adjuvant therapies following pancreatic adenocarcinoma resection.
We reviewed the medical records of 40 patients with locoregional pancreatic adenocarcinoma who underwent tumor resection at Pusan National University Hospital between 2008 and 2012.
Twenty-nine patients were treated with adjuvant therapy comprising either systemic chemotherapy or chemoradiotherapy after curative-intent surgery. Adjuvant therapy (p=0.025) and complete resection (p=0.043) were associated with longer overall survival. There was no significant difference between chemotherapy and chemoradiotherapy in terms of extending overall survival; however, patients who received chemotherapy had significantly higher survival rates than those who received no adjuvant therapy at all (p=0.012).
Adjuvant therapies improve the prognoses of patients with resected pancreatic adenocarcinoma; moreover, chemotherapy produced more favorable outcomes than chemoradiotherapy.


Pancreatic cancer; Chemotherapy; Chemoradiotherapy; Adjuvant
Full Text Links
  • Twitter
  • Facebook
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr